An exceptional safety profile has been shown in a large number of cell therapy clinical trials
that use mesenchymal stromal cells (MSCs). However, reliable potency assays are still …

Research into the mechanisms and manifestations of solid tumor vascularization was
launched more than 50 years ago with the proposition and experimental demonstrations that …

Phenotypic plasticity has emerged as a major contributor to intra-tumoral heterogeneity and
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …

Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

Background: Chitinase-3-like protein 1 (CHI3L1) is overexpressed in various types of
tumors, especially in glioma, and contributes to tumor progression. However, the definite …

The tumor physical microenvironment (TPME) contributes to cancer chemoresistance in both
mechanical and mechanobiological approaches. Along with chemotherapy, the tumor …

Gliomas are the most prevalent and aggressive brain tumors, exhibiting high proliferation,
abnormal glycolysis, and poor prognosis. LncRNAs act as regulatory molecules and play …

Glioblastoma is a primary malignant brain tumor with a median survival under 2 years. The
poor prognosis glioblastoma caries is largely due to cellular invasion, which enables escape …

Cadherins are calcium-binding proteins with a pivotal role in cell adhesion and tissue
homeostasis. The cadherin-dependent mechanisms of cell adhesion and migration are …

The mesenchymal (MES) subtype of glioblastoma (GBM) is a highly aggressive, malignant
and proliferative cancer that is resistant to chemotherapy. Runt-related transcription factor 1 …